What we claim is:

- 1. A method of inhibiting tumor growth in tumors having growth factor receptors comprising administering, about simultaneously, antibodies to the target growth factor receptors, at least one chemotherapeutic agent and radiation therapy.
- 2. The method of claim 1 wherein the first dose of antibodies to target growth factor receptors is administered before or at the time of administration of at least one chemotherapeutic agent.
  - 3. The method of claim 1 wherein the antibody is to a epidermal growth factor receptor or a Her-2/neu receptor.
  - 4. The method of claim 1 wherein the chemotherapeutic agent is chosen from among cisplatin, irinotecan (CPT--11), paclitaxel, gemcitabine, 5-fluorouracil, and doxorubicin.
  - 5. The method of claim 1 wherein the tumor growth to be inhibited is a pancreatic tumor.
  - 6. The method of claim 1 wherein the tumor growth to be inhibited is a colon tumor.
  - 7. The method of claim 1 wherein the antibody administered is one chosen from IMC-C225 and Herceptin.
  - 8. The method of claim 7 wherein the antibody administered is Herceptin.
- 35 9. The method of claim 2 wherein the antibody administered is one chosen from IMC-C225 and Herceptin.

25

30

5

10

- 10. The method of claim 4 wherein the chemotherapeutic agent is gemcitabine.
- 11. The method of claim 1 wherein the antibodies administered are antibodies against epidermal growth factor receptor.
- 12. The method of claim 1 wherein the course of treatment is at least 6 weeks.
- 13. The method of claim 12 wherein the antibodies against a growth factor receptor are administered at a higher dosage at the first dose than at subsequent doses.

15

THE STREET OF BUILDING THE PROPERTY OF THE PRO